Les cytokines: outils et cibles privilégiés dans l'immuno-surveillance du cancer

Abdallah, 1997, Plasma cytokines in graft vs host disease and complications following bone marrow transplantation, Hematol. Cell. Ther, 39, 27, 10.1007/s00282-997-0027-2 Antin, 1994, Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graftversus-host disease, Blood, 84, 1342, 10.1182/blood.V84.4.1342.1342 Asselin-Paturel, 1998, Quantitative analysis of Th1, Th2 and TGF-βl cytokine expression in tumor TIL and PBL of non-small cell lung cancer patients, Int. J. Cancer, 77, 7, 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y Blay, 1989, Functional interactions between IL-2 and TNF in the differentiation of LGL in LAK effectors, Int. J. Cancer, 44, 598, 10.1002/ijc.2910440407 Blay, 1992, Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma, Cancer Res., 52, 3317 Blay, 1996, Lasset, the French Immunotherapy Group Serum IL-6 and CRP in metastatic renal cell carcinoma (MRCC) treated with immunotherapy: identification of subgroups with a high risk of rapid progression, Ann. Oncol., 7, 54 Blay, 1997, Demonstration of the role of interleukin 6 in the paraneoplastic inflammatory syndrom of renal carcinoma, Int. J. Cancer, 72, 424, 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R Boldt, 1988, Laboratory correlates of adoptive immunotherapy with recombinant IL-2 and lymphokine activated killer cells, Cancer. Res, 48, 4409 Bonnotte, 1996, Serum interleukin-12 levels in patients undergoing allogeneic or autologous bone marrow transplantation, Eur. Cytokine. Netw, 7, 389 Borselino, 1996, Effects of an IL-6 receptor superantagonist on the growth and sensitivity to etoposide of hormone resistant and IL-6 secreting prostate carcinoma cells, 37–410 Brunda, 1993, Antitumor and antimetastatic activity of interleukin-12 against murine tumors, J. Exp. Med., 178, 1223, 10.1084/jem.178.4.1223 Cai, 1996, Impairment of Fas Antigen Expression in Adriamycin-Resistance but not TNF-Resistance MCF7 Tumor cells, Int. J. Cancer, 68, 535, 10.1002/(SICI)1097-0215(19961115)68:4<535::AID-IJC21>3.0.CO;2-2 Cai, 1997, Alteration of the Sphingomyelin/Ceramide Pathway is Associated with Resistance of Human Breast Carcinoma MCF7 Cells to Tumor Necrosis Factor-α-Mediated Cytotoxicity, J. Biol. Chem, 272, 6918, 10.1074/jbc.272.11.6918 Cai, 1997, Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function, Oncogene, 15, 2817, 10.1038/sj.onc.1201445 Carayol, 1997, Quantitative analysis of T helper 1, T helper 2 and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation: relationship with the occurrence of acute graft-versus-host disease, Transplantation, 63, 1307, 10.1097/00007890-199705150-00019 Chan, 1991, Induction of IFN production by NK stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers, J. Exp. Med., 173, 869, 10.1084/jem.173.4.869 Chehimi, 1992, Natural Killer cell stimulatory factor (NKSF) increases the cytotoxic activity of NK cells from both healthy donors and Hiv-infected patients, J. Exp. Med, 175, 789, 10.1084/jem.175.3.789 Chehimi, 1993, Enhancing effect of natural killer cell stimulatory factor (NKSF/IL-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells, Eur. J. Immunol., 23, 1826, 10.1002/eji.1830230814 Chehimi, 1994, Impaired interleukin-12 production in human immuno-deficiency virusinfected patients, J. Exp. Med., 179, 1361, 10.1084/jem.179.4.1361 Chouaib, 1988, Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin-2, 85, 6875 Chouaib, 1991, More insights in the complex physiology of TNF, Immunol. Today, 12, 141, 10.1016/S0167-5699(05)80041-6 Chouaib, 1994, Interleukin 12 induces the differenciation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors, 91, 12659 Chouaib, 1997, The Tumor-Host Immune Conflict: From Immuno-suppression to Resistance and Destruction, Immunol. Today, 18, 493, 10.1016/S0167-5699(97)01115-8 Clerici, 1993, Restoration of Hiv-specific cell-mediated immune responses by interleukin-12 in vitro, Science, 262, 1721, 10.1126/science.7903123 Clift, 1990, Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens, Blood, 76, 1867, 10.1182/blood.V76.9.1867.1867 Colombo M.P., Modesti A., Parmiani G., Forni G., Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T lymphocyte cross-talk, Cancer Res. 52, 4853–4857. Dickinson, 1994, Cytokine involvement in predicting clinical graft-versushost disease in allogeneic bone marrow transplant recipients, Bone Marrow Transplant, 13, 65 Ferrara, 1993, Cytokine dysregulation as a mechanism of graft versus host disease, Curr. Opin. Immunol., 5, 794, 10.1016/0952-7915(93)90139-J Fowler, 1994, Donor lymphoid cells of Th2 cytokine phenotype reduce lethal graft versus host disease and facilitate fully allogeneic cell transfers in sublethally irradiated mice, Prog. Clin. Biol. Res., 389, 533 Fowler, 1996, Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and grart-versus-host disease, J. Immunol., 157, 4811, 10.4049/jimmunol.157.11.4811 Fowler, 1996, Allospecific CD4+Th1/Th2 CD8+Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL, Biol. Blood. Marrow. Transplant, 2, 118 Hagenbaugh, 1997, Altered immune responses in interleukin 10 transgenic mice, J. Exp. Med., 185, 2101, 10.1084/jem.185.12.2101 Hakim, 1997, Graft-versus host disease: The immune system: effector and target of graft-versushost disease, 257 Havell, 1988, The anti-tumor function of TNF, J. Exp. Med., 167, 1067, 10.1084/jem.167.3.1067 Herve, 1992, Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease, Blood, 79, 3362, 10.1182/blood.V79.12.3362.bloodjournal79123362 Hill, 1997, Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines, Blood, 90, 3204, 10.1182/blood.V90.8.3204 Holler, 1995, Blood, 86, 890, 10.1182/blood.V86.3.890.890 Hsu, 1995, The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation, Cell, 81, 495, 10.1016/0092-8674(95)90070-5 Krenger, 1995, Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease, J. Immunol., 155, 585, 10.4049/jimmunol.155.2.585 Lienard, 1992, Highdose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J. Clin. Oncol., 10, 52, 10.1200/JCO.1992.10.1.52 Lu, 1993, IL-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression, J. Cell. Biol., 120, 1281, 10.1083/jcb.120.5.1281 Manetti, 1993, Natural Killer cell stimulatory factor (NKSF/IL-12) induces Th1-type specific immune responses and inhibits the development of IL-4 producing Th2 cells, J. Exp. Med., 177, 1199, 10.1084/jem.177.4.1199 Matsuda, 1994, IL-10 pretreatment protect target cells from tumor-and all-specific cytotoxic T cells and downregulates HLA class I expression, J. Exp. Med., 180, 2371, 10.1084/jem.180.6.2371 Mc Carthy, 1996, A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoidresistant graft-versus-host disease, Transplantation, 62, 626, 10.1097/00007890-199609150-00015 Mc Intosh, 1989, Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin-2, alpha-interferon and its synergistic antitumor effects in mice, Cancer Res., 49, 1408 Menetrier-Caux, 1998, IL-6 and M-CSF mediated inhibition of dendritic cell differentiation by dendritic cells, 39 Negrier, 1998, Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma, New. Engl. J. Med., 338, 1272, 10.1056/NEJM199804303381805 Ochs, 1996, Cytokine expression in human cutaneous chronic graft-versus-host disease, Bone Marrow Transplant, 17, 1085 Ostensen, 1987, TNF alpha enhances cytolytic activity of human NK cells, J. Immunol., 138, 4185, 10.4049/jimmunol.138.12.4185 Remberger, 1995, TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD, Bone Marrow Transplant, 15, 99 Robertson, 1992, Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF, J. Exp. Med, 175, 779, 10.1084/jem.175.3.779 Robinet, 1990, Evidence for tumor necrosis factor-α involvement in the optimal induction of class I allospecific cytotoxic T cells, J. Immunol., 144, 4555, 10.4049/jimmunol.144.12.4555 Robinet, 1992, Serum levels and receptor expression of tumor necrosis factor-alpha following human allogeneic and autologous bone marrow transplantation, Transplantation, 53, 574, 10.1097/00007890-199203000-00016 Rook, 1995, Interleukin-12 reverses cytokine and immune abnormalities in Sezary syndrome, J. Immunol., 154, 1491, 10.4049/jimmunol.154.3.1491 Rosenberg, 1989, Experience with the use of high dose interleukin 2 in the treatment of 652 cancer patients, Ann. Surg., 210, 474, 10.1097/00000658-198910000-00008 Rowbottom, 1993, Cytokine gene expression in skin and lymphoidorgans in graft versus host disease, J. Clin. Pathol., 46, 341, 10.1136/jcp.46.4.341 Rus, 1995, Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells, J. Immunol., 155, 2396, 10.4049/jimmunol.155.5.2396 Sodhi, 1992, Increased production of interleukin-1 and tumor necrosis factor by human monocytes treated in vitro with cisplatin or other biological response modifiers, Immunol. Lett., 34, 183, 10.1016/0165-2478(92)90211-6 Soiffer, 1993, Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies, Blood, 82, 2790, 10.1182/blood.V82.9.2790.2790 Spriggs, 1992, Cancer Chemotherapy: experiences with TNF administration in humans, 383 Tanaka, 1997, The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease, Bone Marrow Transplant, 19, 571, 10.1038/sj.bmt.1700708 Tartour, 1996, Predictors of clinical response to interleukin 2 based immunotherapy in melanoma patients: a French multiinstitutional study, J. Clin. Oncol., 14, 1697, 10.1200/JCO.1996.14.5.1697 Torre-Amione, 1990, A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance, 87, 1486 Tracey, 1992, The acute and chronic pathophysiologic effects of TNF: mediation of septic shock and wasting (cachexia), 255 Via, 1994, IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graftversus-host disease, J. Immunol., 153, 4040, 10.4049/jimmunol.153.9.4040 Voest, 1995, Inhibition of angiogenesis in vivo by Interleukin-12, J. Natl. Cancer Inst., 87, 581, 10.1093/jnci/87.8.581 Williamson, 1997, Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease, J. Immunol., 159, 1208, 10.4049/jimmunol.159.3.1208 Wu, 1993, IL-12 induces the production of IFN-γ by neonatal human CD4 T cells, J. Immunol., 151, 1938, 10.4049/jimmunol.151.4.1938 Xun, 1994, Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2 incompatible transplanted SCID mice, Blood, 83, 2360, 10.1182/blood.V83.8.2360.2360 Yang, 1997, Interleukin-12 prevents severe acute graft-versus-host disease (GVHD) and GVHD-associated immune dysfunction in a fully major histocompatibility complex haplotype-mismatched murine bone marrow transplantation model, Transplantation, 64, 1343, 10.1097/00007890-199711150-00018 Yang, 1997, Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice, Blood, 90, 4651, 10.1182/blood.V90.11.4651 Zyad, 1994, Cross Resistance to TNF, Adriamycin: Relationship to MDR1, MnSOD and TNF Gene Expression in the Human Breast Adeno Carcinoma Cell Line MCF7, Cancer Res., 54, 825